Cargando…
Six-month efficacy of platelet-rich plasma for carpal tunnel syndrome: A prospective randomized, single-blind controlled trial
Recently, a few small reports with short follow-up period have shown clinical benefits of platelet-rich plasma (PRP) for peripheral neuropathy including one pilot study and one small, non-randomized trial in patients with carpal tunnel syndrome (CTS). Therefore, we conducted a randomized, single-bli...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5427966/ https://www.ncbi.nlm.nih.gov/pubmed/28273894 http://dx.doi.org/10.1038/s41598-017-00224-6 |
_version_ | 1783235730559991808 |
---|---|
author | Wu, Yung-Tsan Ho, Tsung-Yen Chou, Yu-Ching Ke, Ming-Jen Li, Tsung-Ying Huang, Guo-Shu Chen, Liang-Cheng |
author_facet | Wu, Yung-Tsan Ho, Tsung-Yen Chou, Yu-Ching Ke, Ming-Jen Li, Tsung-Ying Huang, Guo-Shu Chen, Liang-Cheng |
author_sort | Wu, Yung-Tsan |
collection | PubMed |
description | Recently, a few small reports with short follow-up period have shown clinical benefits of platelet-rich plasma (PRP) for peripheral neuropathy including one pilot study and one small, non-randomized trial in patients with carpal tunnel syndrome (CTS). Therefore, we conducted a randomized, single-blind, controlled trial to assess the 6-month effect of PRP in patients with CTS. Sixty patients with unilateral mild-to-moderate CTS were randomized into two groups of 30, namely the PRP and control groups. In the PRP group, patients were injected with one dose of 3 mL of PRP using ultrasound guidance and the control group received a night splint through the study period. The primary outcome measure was the visual analog scale (VAS) and secondary outcome measures included the Boston Carpal Tunnel Syndrome Questionnaire (BCTQ) score, the cross-sectional area (CSA) of the median nerve (MN), electrophysiological findings of the MN, and finger pinch strength. The evaluation was performed before treatment and at 1, 3, and 6 months post-injection. The PRP group exhibited a significant reduction in the VAS score, BCTQ score, and CSA of MN compared to the those of control group 6 months post-treatment (p < 0.05). Our study demonstrates that PRP is a safe modality that effectively relieves pain and improves disability in the patients with CTS. |
format | Online Article Text |
id | pubmed-5427966 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-54279662017-05-15 Six-month efficacy of platelet-rich plasma for carpal tunnel syndrome: A prospective randomized, single-blind controlled trial Wu, Yung-Tsan Ho, Tsung-Yen Chou, Yu-Ching Ke, Ming-Jen Li, Tsung-Ying Huang, Guo-Shu Chen, Liang-Cheng Sci Rep Article Recently, a few small reports with short follow-up period have shown clinical benefits of platelet-rich plasma (PRP) for peripheral neuropathy including one pilot study and one small, non-randomized trial in patients with carpal tunnel syndrome (CTS). Therefore, we conducted a randomized, single-blind, controlled trial to assess the 6-month effect of PRP in patients with CTS. Sixty patients with unilateral mild-to-moderate CTS were randomized into two groups of 30, namely the PRP and control groups. In the PRP group, patients were injected with one dose of 3 mL of PRP using ultrasound guidance and the control group received a night splint through the study period. The primary outcome measure was the visual analog scale (VAS) and secondary outcome measures included the Boston Carpal Tunnel Syndrome Questionnaire (BCTQ) score, the cross-sectional area (CSA) of the median nerve (MN), electrophysiological findings of the MN, and finger pinch strength. The evaluation was performed before treatment and at 1, 3, and 6 months post-injection. The PRP group exhibited a significant reduction in the VAS score, BCTQ score, and CSA of MN compared to the those of control group 6 months post-treatment (p < 0.05). Our study demonstrates that PRP is a safe modality that effectively relieves pain and improves disability in the patients with CTS. Nature Publishing Group UK 2017-03-07 /pmc/articles/PMC5427966/ /pubmed/28273894 http://dx.doi.org/10.1038/s41598-017-00224-6 Text en © The Author(s) 2017 This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ |
spellingShingle | Article Wu, Yung-Tsan Ho, Tsung-Yen Chou, Yu-Ching Ke, Ming-Jen Li, Tsung-Ying Huang, Guo-Shu Chen, Liang-Cheng Six-month efficacy of platelet-rich plasma for carpal tunnel syndrome: A prospective randomized, single-blind controlled trial |
title | Six-month efficacy of platelet-rich plasma for carpal tunnel syndrome: A prospective randomized, single-blind controlled trial |
title_full | Six-month efficacy of platelet-rich plasma for carpal tunnel syndrome: A prospective randomized, single-blind controlled trial |
title_fullStr | Six-month efficacy of platelet-rich plasma for carpal tunnel syndrome: A prospective randomized, single-blind controlled trial |
title_full_unstemmed | Six-month efficacy of platelet-rich plasma for carpal tunnel syndrome: A prospective randomized, single-blind controlled trial |
title_short | Six-month efficacy of platelet-rich plasma for carpal tunnel syndrome: A prospective randomized, single-blind controlled trial |
title_sort | six-month efficacy of platelet-rich plasma for carpal tunnel syndrome: a prospective randomized, single-blind controlled trial |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5427966/ https://www.ncbi.nlm.nih.gov/pubmed/28273894 http://dx.doi.org/10.1038/s41598-017-00224-6 |
work_keys_str_mv | AT wuyungtsan sixmonthefficacyofplateletrichplasmaforcarpaltunnelsyndromeaprospectiverandomizedsingleblindcontrolledtrial AT hotsungyen sixmonthefficacyofplateletrichplasmaforcarpaltunnelsyndromeaprospectiverandomizedsingleblindcontrolledtrial AT chouyuching sixmonthefficacyofplateletrichplasmaforcarpaltunnelsyndromeaprospectiverandomizedsingleblindcontrolledtrial AT kemingjen sixmonthefficacyofplateletrichplasmaforcarpaltunnelsyndromeaprospectiverandomizedsingleblindcontrolledtrial AT litsungying sixmonthefficacyofplateletrichplasmaforcarpaltunnelsyndromeaprospectiverandomizedsingleblindcontrolledtrial AT huangguoshu sixmonthefficacyofplateletrichplasmaforcarpaltunnelsyndromeaprospectiverandomizedsingleblindcontrolledtrial AT chenliangcheng sixmonthefficacyofplateletrichplasmaforcarpaltunnelsyndromeaprospectiverandomizedsingleblindcontrolledtrial |